In vivo, they confirmed that anti-CD19 CAR T cells prolonged survival of the different genetic classes of B-CLL tumor cells and revealed a differential anti-tumor efficacy according to the mutation introduced [87]. This evidence concerns the gene CD19 and neoplasm.